Polybrominated diphenyl ethers in relation to autism and developmental delay: a case-control study
Irva Hertz-Picciotto1, Ake Bergman, Britta Fängström
1Department of Public Health Sciences, School of Medicine, University of California, MS1C, One Shields Ave., Davis, California, USA. ihp@ucdavis.edu
Insights
This study found no association between current Polybrominated Diphenyl Ethers (PBDEs) levels and autism. High PBDE levels were observed in children with autism, developmental delay, and controls, suggesting later measurements may not reflect early life exposures.
Area of Science:
- Environmental Health
- Neurodevelopmental Disorders
- Toxicology
Background:
- Polybrominated diphenyl ethers (PBDEs) are flame retardants increasingly used in the U.S.
- PBDEs cross the placenta and rodent studies indicate neurodevelopmental toxicity from prenatal exposure.
- Children are exposed to PBDEs through breastfeeding and hand-to-mouth activities.
Purpose of the Study:
- To investigate the association between Polybrominated Diphenyl Ethers (PBDEs) and autism spectrum disorder (ASD) in children.
- To evaluate PBDE congener levels in children diagnosed with autism, developmental delay, and typically developing controls.
Main Methods:
- A case-control study involving 100 children from the CHildhood Autism Risk from Genetics and the Environment (CHARGE) Study.
- Autism and developmental delay diagnoses confirmed using standardized assessments.
- Gas chromatography/mass spectrometry used to measure eleven PBDE congeners in serum samples; logistic regression analyzed associations.
Main Results:
- No significant differences in PBDE congener levels were found between children with autism/developmental delay and typically developing controls.
- All participant groups exhibited high levels of PBDEs, indicating widespread exposure.
- Current plasma PBDE levels did not correlate with autism diagnosis in this cohort.
Conclusions:
- Plasma samples collected post-diagnosis may not accurately reflect early-life PBDE exposures.
- Further research measuring prenatal or infant exposures is necessary to determine a causal role for PBDEs in autism spectrum disorders.
- The study highlights the need for longitudinal studies to understand the impact of early environmental exposures on neurodevelopment.
Background:
Polybrominated diphenyl ethers (PBDEs) are flame retardants used widely and in increasing amounts in the U.S. over the last few decades. PBDEs and their metabolites cross the placenta and studies in rodents demonstrate neurodevelopmental toxicity from prenatal exposures. PBDE exposures occur both via breastfeeding and hand-to-mouth activities in small children.
Methods:
Participants were 100 children from the CHARGE (CHildhood Autism Risk from Genetics and the Environment) Study, a case-control epidemiologic investigation of children with autism/autism spectrum disorder, with developmental delay and from the general population. Diagnoses of autism were confirmed by the Autism Diagnostic Observation Schedule and Autism Diagnostic Inventory-Revised, and of developmental delay using the Mullen's Scales of Early Learning and the Vineland Adaptive Behavior Scales. Typically developing controls were those with no evidence of delay, autism, or autism spectrum disorder. Eleven PBDE congeners were measured by gas chromatography/mass spectrometry from serum specimens collected after children were assessed. Logistic regression was used to evaluate the association between plasma PBDEs and autism.
Results:
Children with autism/autism spectrum disorder and developmental delay were similar to typically developing controls for all PBDE congeners, but levels were high for all three groups.
Conclusions:
Plasma samples collected post-diagnosis in this study may not represent early life exposures due to changes in diet and introduction of new household products containing PBDEs. Studies with direct measurements of prenatal or infant exposures are needed to assess the possible causal role for these compounds in autism spectrum disorders.
Related Concept Videos
Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Pedigree Analysis

